Skip to main
  1. Stocks
  2. Erasca Inc
  3. Forecast
ERAS

Erasca Inc (ERAS) Stock Forecast & Price Target

Erasca Inc (ERAS) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Erasca is attractive because its lead pan-RAS asset, ERAS-0015, is showing increasingly credible efficacy across PDAC and NSCLC while maintaining relatively clean tolerability, including a 57% uORR in seven evaluable 2L+ KRAS G12X PDAC patients and a 60% uORR in the U.S. lung dataset. The company also has multiple near-term catalysts, with first ERAS-4001 clinical data expected in 2H26 and potentially registration-enabling studies for ERAS-0015 planned for 2027, which broadens the upside beyond a single program. Financially, 2Q26 net loss was $44.1M, cash, cash equivalents, and marketable securities were $384.3M at quarter-end, and the July 2026 public offering added $632.5M in gross proceeds, strengthening the balance sheet to fund the outlined milestones.

Bears say

Erasca is a clinical-stage company with no approved products, so its valuation depends heavily on a small RAS/MAPK-focused pipeline that remains exposed to clinical, regulatory, and commercial setbacks. Its lead assets, ERAS-0015 and ERAS-4001, are still in development, and the discovery-stage ERAS-12 adds further uncertainty rather than near-term diversification. The negative outlook is reinforced by the explicit risk of new competitors, lower-than-expected product sales, intellectual property challenges, management execution issues, and possible M&A missteps, all of which could undermine shareholder value.

Erasca Inc (ERAS) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Erasca Inc and is not a guaranteed prediction by Public.com or investment advice.

Erasca Inc (ERAS) Analyst Forecast & Price Prediction

Get the latest Erasca Inc (ERAS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Erasca Inc (ERAS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Erasca Inc (ERAS) Forecast

Analysts have given Erasca Inc (ERAS) a Buy based on their latest research and market trends.

According to 10 analysts, Erasca Inc (ERAS) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Erasca Inc (ERAS)


Erasca Inc (ERAS) Analyst Forecast & Price Prediction

Get the latest Erasca Inc (ERAS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Erasca Inc (ERAS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ERAS stock data and trends